Jinbo Yue
Study Principal Investigator · Shandong Cancer Hospital and Institute · Shandong Cancer Hospital and Institute, Department of Radiation Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
19
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in pancreatic cancer
0
PubMed author-name match
Trials
Studies that name Jinbo Yue as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:10 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07686640 · Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal CancerShandong Cancer Hospital and Institute · recruiting · Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy · principal investigator
- Ph2NCT07683221 · SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic CancerShandong Cancer Hospital and Institute · recruiting · Pancreatic Cancer · principal investigator
- N/ANCT07595107 · Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal CancerShandong Cancer Hospital and Institute · recruiting · Rectal Cancer · principal investigator
- N/ANCT07408505 · Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic CancerShandong Cancer Hospital and Institute · recruiting · Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome · principal investigator
- Ph2NCT07173387 · Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic CancerShandong Cancer Hospital and Institute · recruiting · Pancreatic Cancer · principal investigator
- Ph1NCT07173374 · Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility StudyShandong Cancer Hospital and Institute · suspended · Pancreatic Cancer, Locally Advanced Pancreatic Cancer · principal investigator
- Ph2NCT07062055 · BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesShandong Cancer Hospital and Institute · recruiting · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases · principal investigator
- Ph2NCT07030140 · Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaJinbo Yue · recruiting · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer · principal investigator
- Ph2NCT07026422 · Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)Shandong Cancer Hospital and Institute · recruiting · Rectal Malignant Neoplasms · principal investigator
- Ph2NCT07007182 · Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerJinbo Yue · recruiting · Gastric Adenocarcinoma, Stomach Neoplasms · principal investigator
- N/ANCT06987370 · SFRT and SCART in Radiotherapy for Bone Metastases With Soft TissueShandong Cancer Hospital and Institute · recruiting · Bone Metastases in Subjects With Advanced Cancer · principal investigator
- N/ANCT06980259 · Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue SarcomaShandong Cancer Hospital and Institute · recruiting · Soft Tissue Sarcoma (STS) · principal investigator
- Ph3NCT06850090 · Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III TrialShandong Cancer Hospital and Institute · recruiting · Rectal Cancer, Rectal Cancer Patients · principal investigator
- Ph1/Ph2NCT06844422 · Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)Shandong Cancer Hospital and Institute · recruiting · Pancreatic Cancer · principal investigator
- Ph3NCT06841172 · Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCShandong Cancer Hospital and Institute · recruiting · OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy · principal investigator
- Ph2NCT06778382 · Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.Shandong Cancer Hospital and Institute · recruiting · Colorectal Neoplasms Malignant · principal investigator
- N/ANCT06443632 · WASPE Sleep Adjustment for Children Aged 0-4 Years Undergoing Radiation TherapyShandong Cancer Hospital and Institute · completed · Pediatric Cancer · principal investigator
- Ph3NCT06246344 · Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal CancerShandong Cancer Hospital and Institute · active not recruiting · Rectal Cancer · principal investigator
- Ph2NCT06050317 · Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic CancerShandong Cancer Hospital and Institute · recruiting · Pancreas Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.